Go Deep
RaQualia Pharma Inc.
RaQualia Pharma Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 23,729 | 71.3 | 2.07 | 0.34 | 377.75 |
| Oct 2026 | 23,568 | 74.9 | 2.18 | 0.34 | 395.75 |
RaQualia Pharma Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 653,599,000.0 | 801,993,000.0 | 1,668,931,000.0 | 775,053,000.0 |
| Net Profit | -240,950,000.0 | -225,693,000.0 | 842,099,000.0 | -214,237,000.0 |
| EPS | — | -8.8 | — | — |
RaQualia Pharma Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 3,979,956,000.0 | 3,107,575,000.0 | 1,901,202,000.0 | 2,918,038,000.0 | — |
| Net Profit | 273,115,000.0 | -495,031,000.0 | -323,662,000.0 | 723,390,000.0 | — |
| EPS | 11.5 | -22.9 | -15.0 | 34.5 | — |
RaQualia Pharma Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 10,514,193,000.0 | 9,655,482,000.0 | 6,871,972,000.0 | 6,257,653,000.0 | — |
| Total Liabilities | 3,617,931,000.0 | 4,084,972,000.0 | 751,530,000.0 | 760,673,000.0 | — |
| Total Equity | 6,896,262,000.0 | 5,570,510,000.0 | 6,120,442,000.0 | 5,496,980,000.0 | — |
Owes vs Owns
RaQualia Pharma Inc. owed ¥0.29 for every ¥1 it owned in Jun 2026, up from ¥0.12 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.29× | 0.34× | 0.42× | 0.11× | 0.12× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
RaQualia Pharma Inc. Assets & Liabilities Breakdown (JPY millions)
What it owns — Dec 2025
Cash & short-term investments 30.9%Receivables 18.3%Inventory 1.5%Fixed assets (tangible) 4.2%Intangible assets 35.5%Long-term investments 5.2%Other assets 4.4%
How it's funded — Dec 2025
Short-term debt 4.9%Long-term debt 20.3%Payables 0.7%Other liabilities 8.5%Shareholders' equity 65.6%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 3,244.3 | 3,341.9 | 3,764.7 | 3,926.0 |
| Receivables | 1,928.3 | 689.2 | 603.2 | 602.3 |
| Inventory | 159.8 | 167.7 | 147.9 | 8.5 |
| Fixed assets (tangible) | 436.4 | 529.1 | 573.6 | 391.0 |
| Intangible assets | 3,732.9 | 3,902.3 | 30.2 | 24.3 |
| Long-term investments | 546.9 | 547.1 | 1,231.5 | 988.0 |
| Other assets | 465.7 | 478.3 | 520.8 | 317.5 |
| Liabilities & equity | ||||
| Short-term debt | 512.6 | 512.6 | 12.6 | 2.6 |
| Long-term debt | 2,138.8 | 2,651.4 | 39.0 | 9.2 |
| Payables | 73.2 | 59.3 | 54.2 | 128.1 |
| Other liabilities | 893.3 | 861.6 | 645.7 | 620.8 |
| Shareholders' equity | 6,896.3 | 5,570.5 | 6,120.4 | 5,497.0 |
| Net tangible assets | 3,163.4 | 1,668.2 | 6,090.3 | 5,472.7 |
RaQualia Pharma Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -354,426,000.0 | 180,945,000.0 | -718,596,000.0 | 1,480,084,000.0 | — |
| Investing Activities | 124,321,000.0 | -3,665,610,000.0 | -135,373,000.0 | -47,649,000.0 | — |
| Financing Activities | 378,064,000.0 | 2,982,105,000.0 | 793,450,000.0 | -29,563,000.0 | — |